Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 10/20 | 1.00 |
| ▸ | GSK3A | P49840 | 6/20 | 1.00 |
| ▸ | PRKCA | P17252 | 2/20 | 1.00 |
| ▸ | RGS4 | P49798 | 10/20 | 0.72 |
| ▸ | RGS8 | P57771 | 10/20 | 0.72 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.66 |
| ▸ | CDK1 | P06493 | 1/20 | 0.66 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.66 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2107216 | 0.88 | GSK3B (1.00) | GSK3BGSK3APRKCARGS4RGS8 | |
| SCHEMBL23763500 | 0.87 | GSK3B (0.77) | GSK3BGSK3APRKCARGS4RGS8 | |
| SCHEMBL15212631 | 0.87 | GSK3B (0.78) | GSK3BGSK3APRKCARGS4RGS8 | |
| SCHEMBL29239064 | 0.85 | RGS4 (0.75) | GSK3BGSK3APRKCARGS4RGS8 | |
| SCHEMBL29210519 | 0.85 | RGS4 (0.75) | GSK3BGSK3APRKCARGS4RGS8 | |
| SCHEMBL13562490 | 0.84 | RGS4 (0.75) | GSK3BGSK3APRKCARGS4RGS8 | |
| SCHEMBL23763661 | 0.84 | RGS4 (0.73) | GSK3BGSK3APRKCARGS4RGS8 | |
| SCHEMBL3383820 | 0.84 | GSK3B (0.72) | GSK3BGSK3APRKCARGS4RGS8 | |
| SCHEMBL13517254 | 0.84 | RGS4 (1.00) | GSK3BGSK3APRKCARGS4RGS8 | |
| SCHEMBL29210530 | 0.84 | RGS4 (0.73) | GSK3BGSK3APRKCARGS4RGS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10344266-B2 | Cell mass capable of serving as a primitive organ-like structure comprised of a plurality of cell types of somatic origin | SHISEIDO COMPANY, LTD. (JP) | 2019-07-09 | — | — | US | claimed |
| EP-2455111-B1 | CELL MASS CAPABLE OF SERVING AS A PRIMITIVE ORGAN-LIKE STRUCTURE COMPRISED OF A PLURALITY OF CELL TYPES OF SOMATIC ORIGIN | SHISEIDO CO LTD (JP) | 2017-08-16 | — | — | EP | claimed |
| US-20160160185-A1 | CELL MASS CAPABLE OF SERVING AS A PRIMITIVE ORGAN-LIKE STRUCTURE COMPRISED OF A PLURALITY OF CELL TYPES OF SOMATIC ORIGIN | SHISEIDO COMPANY, LTD. (JP) | 2016-06-09 | — | — | US | claimed |
| US-8563309-B2 | Primitive organ-like structure comprising keratinocytes and hair papilla cells | SHISEIDO COMPANY, LTD. (JP) | 2013-10-22 | — | — | US | claimed |
| EP-2034011-B1 | CELL CLUSTER COMPRISING PLURAL KINDS OF CELLS DERIVED FROM SOMA WITH ABILITY TO FORM PRIMITIVE ORGAN-LIKE STRUCTURE | SHISEIDO CO LTD (JP) | 2013-05-22 | — | — | EP | claimed |
| EP-2455111-B1 | CELL MASS CAPABLE OF SERVING AS A PRIMITIVE ORGAN-LIKE STRUCTURE COMPRISED OF A PLURALITY OF CELL TYPES OF SOMATIC ORIGIN | SHISEIDO CO LTD (JP) | 2017-08-16 | — | — | EP | disclosed |
| EP-2034011-B1 | CELL CLUSTER COMPRISING PLURAL KINDS OF CELLS DERIVED FROM SOMA WITH ABILITY TO FORM PRIMITIVE ORGAN-LIKE STRUCTURE | SHISEIDO CO LTD (JP) | 2013-05-22 | — | — | EP | disclosed |
| US-7781463-B2 | Enzyme inhibitors | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2010-08-24 | — | — | US | disclosed |
| US-7666885-B2 | Neurodegenerative disease; anticancer agents; hyperplasia; arterosclerosis; restenosis; non-insulin dependent diabetis; Alzheimer's disease | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2010-02-23 | — | — | US | disclosed |
| EP-2034011-A1 | CELL CLUSTER COMPRISING PLURAL KINDS OF CELLS DERIVED FROM SOMA WITH ABILITY TO FORM PRIMITIVE ORGAN-LIKE STRUCTURE | Shiseido Company, Limited (JP) | 2009-03-11 | — | — | EP | disclosed |
| US-20080033012-A1 | Enzyme inhibitors | COSENJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS, A SPAIN CORPORATION | 2008-02-07 | — | — | US | disclosed |
| US-6872737-B2 | Heterocyclic inhibitors of glycogen synthase kinase GSK-3 | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2005-03-29 | — | — | US | disclosed |
| US-20050014803-A1 | Enzyme inhibitors | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS, A SPAIN CORPORATION | 2005-01-20 | — | — | US | disclosed |
| US-20030195238-A1 | Drugs such as 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5 -dione inhibitors of glycogen synthase kinase-3 (GSK-3), for prophylaxis of neurodegenerative disorders, cancer, hyperplasia, psoriasis, arteriosclerosis or restinosis | UNIVERSIDAD AUTONOMA DE MADRID (UAM) (ES) | 2003-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033012-A1 | Enzyme inhibitors | GSK3B, GSK3A, IDE | GSK3B 1/4885GSK3A 2/4885PRKCA 505/4885 |
| US-20030195238-A1 | Drugs such as 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5 -dione inhibitors of glycogen synthase kinase-3 (GSK-3), for prophylaxis of neurodegenerative disorders, cancer, hyperplasia, psoriasis, arteriosclerosis or restinosis | GSK3B, GSK3A, GSKIP | GSK3B 1/4885GSK3A 2/4885PRKCA 643/4885 |
| US-20050014803-A1 | Enzyme inhibitors | GSK3B, GSK3A, IDE | GSK3B 1/4885GSK3A 2/4885PRKCA 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.